2026-10-19 10:22:06 UTC#479610newconfirmednews
BLTE stock news
BLTE stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-15 10:59:26 UTC#465022newconfirmednews
HC Wainwright reiterates Buy on Belite Bio, maintains $245 price target citing Japan NDA for tinlarebant
tradingviewimportance 0.40trust 0.60H.C. Wainwright & Co. 0Belite Bio, Inc. +0.40tinlarebant +0.40+2 entities
2026-10-14 21:01:58 UTC#461786newconfirmednews
Belite Bio submits Tinlarebant marketing applications in Singapore, UK, Switzerland; US PDUFA set for Feb 12, 2027
reutersimportance 0.50trust 0.80Belite Bio, Inc. +0.50Tinlarebant +0.50Stargardt disease +0.50+1 entities
2026-09-21 03:21:38 UTC#340057newconfirmednews
Guggenheim raises BlossomHill Therapeutics price target to $40 from $30
first_squawkimportance 0.30trust 0.70BlossomHill Therapeutics, Inc. +0.40Guggenheim Partners, LLC +0.20
2026-09-18 11:00:00 UTC#332828updateconfirmednews
BlossomHill Therapeutics (BLSM) reports Q2 loss of $8.75 per share
2026-09-18 11:00:00 UTC#332827newconfirmeddata release
BlossomHill Therapeutics (BLSM) reports Q2 2026 net loss of $23.8 million
2026-09-15 19:11:44 UTC#316334newconfirmednews
BlossomHill (BBOT) reprioritizes BBO-8520 for second-line oncology; cash runway extended through 2028
2026-09-15 15:40:14 UTC#315077duplicateconfirmednews
BlossomHill reports positive phase I data for EGFR inhibitor in C797S-resistant cancer patients
2026-09-15 15:21:27 UTC#314962newconfirmednews
BlossomHill reports strong efficacy for lead EGFR inhibitor in resistant cancers; 2027 data readouts ahead
2026-09-15 14:03:17 UTC#314392duplicateconfirmednews
Belite Bio (BLTE) Tinlarebant shows efficacy in Stargardt disease; company highlights commercial readiness
2026-09-15 13:37:58 UTC#314211updateconfirmednews
Belite Bio's Tinlarebant shows strong clinical efficacy and commercial readiness for Stargardt disease
2026-09-14 13:42:55 UTC#307761newconfirmednews
Belite Bio's Tinlarebant shows 36% slower lesion growth in Stargardt disease; FDA decision due February
quartrimportance 0.60trust 0.60Belite Bio, Inc. +0.70Tinlarebant +0.70Stargardt disease +0.70+1 entities
2026-09-11 15:55:40 UTC#299713newconfirmednews
Belite Bio reports 36% lesion growth reduction for Tinlarebant in Stargardt disease, cites regulatory progress
quartrimportance 0.50trust 0.50Belite Bio, Inc. +0.60Tinlarebant +0.60Food and Drug Administration +0.40+1 entities
2026-09-08 15:30:00 UTC#282001newconfirmednews
H.C. Wainwright raises Belite Bio (BLTE) price target to $245 from $214
2026-09-08 14:21:23 UTC#281454duplicateconfirmednews
Belite Bio's tinlarebant remains under FDA priority review for Stargardt disease with February decision expected
quartrimportance 0.30trust 0.50Belite Bio, Inc. +0.50Tinlarebant +0.50Food and Drug Administration +0.40+2 entities
2026-09-08 13:41:27 UTC#281174duplicateconfirmednews
Belite Bio advances tinlarebant commercialization plans following FDA priority review grant
quartrimportance 0.30trust 0.60Belite Bio, Inc. +0.50Tinlarebant +0.50Food and Drug Administration +0.30
2026-09-08 10:13:58 UTC#279744newconfirmednews
Belite Bio submits Tinlarebant NDA in Japan; FDA grants priority review with Feb 12, 2027 PDUFA date
reutersimportance 0.60trust 0.80Belite Bio, Inc. +0.60Tinlarebant +0.60Stargardt disease +0.50+1 entities
2026-09-02 16:03:32 UTC#257152updateconfirmednews
BlossomHill's Tinlarebant shows reduced Stargardt lesion growth; U.S. launch targeted for March 2027
quartrimportance 0.50trust 0.60BlossomHill Therapeutics, Inc. +0.60Tinlarebant +0.60Stargardt disease +0.50
2026-09-02 14:26:46 UTC#256555newconfirmednews
BlossomHill Therapeutics' Tinlarebant granted FDA priority review for Stargardt disease
quartrimportance 0.60trust 0.60BlossomHill Therapeutics, Inc. +0.60Tinlarebant +0.60Stargardt disease +0.50+1 entities
2026-09-01 18:58:00 UTC#251539newconfirmednews